Real World Outcomes of Patients with Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation after Induction with Liposomal Daunorubicin-Cytarabine (CPX-351)

被引：0
|
作者：
Kaleka, Guneet [1 ]
Ngo, Dat [2 ]
Yang, Dongyun [3 ]
Mokhtari, Sally [4 ]
Marcucci, Guido [5 ]
Nakamura, Ryotaro [6 ]
Pullarkat, Vinod [7 ,8 ]
Oliai, Caspian H. [9 ]
Salhotra, Amandeep [10 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] City Hope Natl Med Ctr, Pharm, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Computat & Quantitat Med, Duarte, CA 91010 USA
[4] City Hope Natl Med Ctr, Clin & Translat Project Dev, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Hematol Malignancies & Stem Cell Transplantat Ins, Dept Hematol Malignancies Translat Sci, Gehr Family Ctr Leukemia Res,Beckman Res Inst, Duarte, CA 91010 USA
[6] City Hope Natl Comprehens Canc Ctr, Hematol Malignancies & Stem Cell Transplantat Ins, Duarte, CA USA
[7] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA
[8] City Hope Comprehens Canc Ctr, Gehr Family Ctr Leukemia Res, Duarte, CA USA
[9] UCLA Med Ctr, Dept Med, Div Hematol & Oncol, Los Angeles, CA USA
[10] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-183053
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
615
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia
    Ronson, Aaron
    Tvito, Ariella
    Rowe, Jacob M.
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (04): : 369 - 374
  • [2] Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia
    Asghari, Hannah
    Lancet, Jeffrey
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1305 - 1312
  • [3] CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia
    Cafaro, Alessandro
    Giannini, Maria B.
    Silimbani, Paolo
    Cangini, Delia
    Masini, Carla
    Di Rora, Andrea Ghelli Luserna
    Simonetti, Giorgia
    Martinelli, Giovanni
    Cerchione, Claudio
    MINERVA MEDICA, 2020, 111 (05) : 455 - 466
  • [4] Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
    Chen, Evan C.
    Fathi, Amir T.
    Brunner, Andrew M.
    ONCOTARGETS AND THERAPY, 2018, 11 : 3425 - 3434
  • [5] Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)
    Salhotra, Amandeep
    Aribi, Ahmed
    Ngo, Dat
    Zhang, Jianying
    Sandhu, Karamjeet
    Al-Malki, Monzr
    Ali, Haris
    Koller, Paul
    Arslan, Shukaib
    Budde, Elizabeth
    Khaled, Samer
    Dadwal, Sanjeet
    Snyder, David S.
    Artz, Andrew
    Forman, Stephen
    Nakamura, Ryotaro
    Stein, Anthony
    Marcucci, Guido
    Aldoss, Ibrahim
    Pullarkat, Vinod
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : E196 - E200
  • [6] Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia
    Przespolewski, Amanda
    Talati, Chetasi
    Vachhani, Pankit
    Sanikommu, Srinivasa Reddy
    Thota, Swapna
    Baron, Jeffrey
    Griffiths, Elizabeth A.
    Thompson, James E.
    Sweet, Kendra L.
    Wang, Eunice S.
    BLOOD, 2018, 132
  • [7] Real World Outcomes of CPX-351 Compared to Traditional Chemotherapy with Cytarabine Consolidation for Treatment of Secondary Acute Myeloid Leukemia
    Granger, Katelynn
    Gaffney, Kelly J.
    Smith, Deidra
    Weeda, Erin
    Baratam, Praneeth
    Green, Kimberly Michelle
    Coltoff, Alexander
    Davis, James A.
    BLOOD, 2023, 142
  • [8] Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia
    Grenet, Justin
    Jain, Akriti G.
    Burkart, Madelyn
    Waksal, Julian
    Famulare, Christopher
    Numan, Yazan
    Stahl, Maximilian
    Mckinnell, Zoe
    Ball, Brian
    Ma, Xiaoyue
    Christos, Paul J.
    Ritchie, Ellen
    Samuel, Michael B.
    Kaner, Justin D.
    Lee, Sangmin
    Goldberg, Aaron D.
    Dinner, Shira
    Sweet, Kendra
    Roboz, Gail J.
    Desai, Pinkal
    BLOOD, 2021, 138
  • [9] Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia
    Bewersdorf, Jan Philipp
    Goshua, George
    Patel, Kishan K.
    Shallis, Rory M.
    Podoltsev, Nikolai
    Huntington, Scott F.
    Zeidan, Amer M.
    BLOOD, 2021, 138
  • [10] Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia
    Benitez, Lydia L.
    Perissinotti, Anthony J.
    Rausch, Caitlin R.
    Klaus, Jeff
    Clark, Stephen Michael
    Filtz, Michael
    Ratermann, Kelley
    Treptow, Carissa
    Griffin, Shawn
    Olson, Marissa
    Crain, Mallory
    Kadia, Tapan
    Pettit, Kristen
    Burke, Patrick W.
    Bixby, Dale L.
    Marini, Bernard L.
    LEUKEMIA & LYMPHOMA, 2021, 62 (09) : 2184 - 2192
12345